RAMM Pharma Corp. (CSE:RAMM)
Canada · Delayed Price · Currency is CAD 0.0150
+0.0050 (50.00%)
Oct 7, 2025, 10:17 AM EDT
RAMM Pharma Income Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | 2018 - 2019 |
| 3.78 | 4.34 | 5.07 | 3.9 | 4.12 | 5.44 | Upgrade | |
Revenue Growth (YoY) | -15.51% | -14.28% | 29.97% | -5.31% | -24.40% | -2.96% | Upgrade |
Cost of Revenue | 2.88 | 2.57 | 4.64 | 3.41 | 4.15 | 4.17 | Upgrade |
Gross Profit | 0.9 | 1.78 | 0.42 | 0.48 | -0.04 | 1.27 | Upgrade |
Selling, General & Admin | 6.28 | 8.42 | 7.36 | 8.42 | 6.6 | 8.85 | Upgrade |
Other Operating Expenses | 0.11 | 0.12 | 0.15 | - | - | - | Upgrade |
Operating Expenses | 7.82 | 10.72 | 7.51 | 8.42 | 6.6 | 8.85 | Upgrade |
Operating Income | -6.92 | -8.94 | -7.09 | -7.94 | -6.64 | -7.58 | Upgrade |
Interest Expense | -0.06 | -0.04 | -0.05 | -0.01 | -0.01 | -0.06 | Upgrade |
Interest & Investment Income | - | 0.03 | 0.2 | 0.16 | 0.37 | 0.33 | Upgrade |
Earnings From Equity Investments | - | - | - | - | -0.71 | - | Upgrade |
Currency Exchange Gain (Loss) | -0.03 | -0 | -0.04 | 0.08 | -0.3 | -0.13 | Upgrade |
Other Non Operating Income (Expenses) | 0.81 | 0.02 | 0.35 | 0.17 | 0.03 | - | Upgrade |
EBT Excluding Unusual Items | -6.2 | -8.93 | -6.64 | -7.54 | -7.26 | -7.43 | Upgrade |
Impairment of Goodwill | - | - | - | -12.93 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -0.23 | 0.27 | - | Upgrade |
Asset Writedown | -7.56 | -7.56 | -1.07 | -0.25 | - | - | Upgrade |
Other Unusual Items | - | - | - | - | -0.11 | - | Upgrade |
Pretax Income | -13.22 | -16.49 | -7.71 | -20.95 | -7.1 | -7.43 | Upgrade |
Income Tax Expense | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade |
Net Income | -13.24 | -16.5 | -7.72 | -20.96 | -7.11 | -7.43 | Upgrade |
Net Income to Common | -13.24 | -16.5 | -7.72 | -20.96 | -7.11 | -7.43 | Upgrade |
Shares Outstanding (Basic) | 119 | 119 | 121 | 123 | 108 | 101 | Upgrade |
Shares Outstanding (Diluted) | 119 | 119 | 121 | 123 | 108 | 101 | Upgrade |
Shares Change (YoY) | 0.01% | -1.36% | -1.42% | 13.20% | 7.85% | 99.46% | Upgrade |
EPS (Basic) | -0.11 | -0.14 | -0.06 | -0.17 | -0.07 | -0.07 | Upgrade |
EPS (Diluted) | -0.11 | -0.14 | -0.06 | -0.17 | -0.07 | -0.07 | Upgrade |
Free Cash Flow | -1.61 | -4.05 | -4.4 | -6.08 | -4.26 | -3.19 | Upgrade |
Free Cash Flow Per Share | -0.01 | -0.03 | -0.04 | -0.05 | -0.04 | -0.03 | Upgrade |
Gross Margin | 23.76% | 40.92% | 8.34% | 12.43% | -0.91% | 23.40% | Upgrade |
Operating Margin | -183.22% | -205.86% | -139.90% | -203.64% | -161.37% | -139.14% | Upgrade |
Profit Margin | -350.49% | -380.06% | -152.43% | -537.79% | -172.66% | -136.47% | Upgrade |
Free Cash Flow Margin | -42.50% | -93.17% | -86.87% | -156.02% | -103.52% | -58.61% | Upgrade |
EBITDA | -6.37 | -7.97 | -6.03 | -7 | -6.01 | -7.24 | Upgrade |
EBITDA Margin | -168.79% | -183.47% | -119.00% | -179.69% | -145.94% | -132.89% | Upgrade |
D&A For EBITDA | 0.54 | 0.97 | 1.06 | 0.93 | 0.63 | 0.34 | Upgrade |
EBIT | -6.92 | -8.94 | -7.09 | -7.94 | -6.64 | -7.58 | Upgrade |
EBIT Margin | -183.22% | -205.86% | -139.90% | -203.64% | -161.37% | -139.14% | Upgrade |
Advertising Expenses | - | 0.06 | 0.2 | 0.42 | 0.09 | 0.08 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.